IN2014DN09348A - - Google Patents

Info

Publication number
IN2014DN09348A
IN2014DN09348A IN9348DEN2014A IN2014DN09348A IN 2014DN09348 A IN2014DN09348 A IN 2014DN09348A IN 9348DEN2014 A IN9348DEN2014 A IN 9348DEN2014A IN 2014DN09348 A IN2014DN09348 A IN 2014DN09348A
Authority
IN
India
Prior art keywords
compounds
disorders
substituents
useful
formula
Prior art date
Application number
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Matthew C Lucas
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014DN09348A publication Critical patent/IN2014DN09348A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof wherein the substituents are as those disclosed in the specification. These compounds and the pharmaceutical compositions containing them are useful for the treatment of inflammatory diseases and disorders such as for example pulmonary fibrosis...
IN9348DEN2014 2012-06-20 2013-06-17 IN2014DN09348A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20
PCT/EP2013/062461 WO2013189864A1 (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
IN2014DN09348A true IN2014DN09348A (en) 2015-07-17

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9348DEN2014 IN2014DN09348A (en) 2012-06-20 2013-06-17

Country Status (22)

Country Link
US (1) US9321738B2 (en)
EP (1) EP2864300A1 (en)
JP (1) JP2015520202A (en)
KR (1) KR20150021057A (en)
CN (1) CN104411692A (en)
AU (1) AU2013279512A1 (en)
BR (1) BR112014030685A2 (en)
CA (1) CA2869541A1 (en)
CL (1) CL2014003243A1 (en)
CO (1) CO7131358A2 (en)
CR (1) CR20140525A (en)
EA (1) EA201492285A1 (en)
HK (1) HK1206342A1 (en)
IL (1) IL236088A0 (en)
IN (1) IN2014DN09348A (en)
MA (1) MA37764A1 (en)
MX (1) MX2014014710A (en)
PE (1) PE20142448A1 (en)
PH (1) PH12014502789A1 (en)
SG (1) SG11201407220YA (en)
UA (1) UA109868C2 (en)
WO (1) WO2013189864A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
JP2015520203A (en) * 2012-06-20 2015-07-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ N-aryltriazole compounds as LPAR antagonists
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
AR108838A1 (en) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co CARBAMOYLOXIMETHYL ACID TRIAZOL CYCLOHEXILO AS LPA ANTAGONISTS
KR102698386B1 (en) 2017-12-19 2024-08-22 브리스톨-마이어스 스큅 컴퍼니 Pyrazole N-linked carbamoyl cyclohexyl acid as an LPA antagonist
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
CN112074515B (en) 2017-12-19 2025-01-10 百时美施贵宝公司 Cyclohexyl acid isoxazolidinones as LPA antagonists
JP7202383B2 (en) 2017-12-19 2023-01-11 ブリストル－マイヤーズ スクイブ カンパニー Pyrazole O-bridged carbamoylcyclohexylates as LPA antagonists
TW202017918A (en) * 2017-12-19 2020-05-16 美商必治妥美雅史谷比公司 Cyclohexyl acid triazole azines as lpa antagonists
JP7526096B2 (en) * 2017-12-19 2024-07-31 ブリストル－マイヤーズ スクイブ カンパニー Cyclohexyl isoxazole azines as LPA antagonists
KR102697358B1 (en) 2017-12-19 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 Isoxazole O-linked carbamoyl cyclohexyl acid as an LPA antagonist
EP3728210B1 (en) 2017-12-19 2026-02-11 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
US10662172B2 (en) * 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
KR20200100713A (en) * 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Cyclohexyl acid triazole azole as an LPA antagonist
US11312706B2 (en) 2017-12-19 2022-04-26 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as LPA antagonists
IL297802A (en) * 2017-12-29 2022-12-01 Biomarin Pharm Inc Glycolate oxidase inhibitors for the treatment of disease
ES2946657T3 (en) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Cyclopentyl acids as LPA antagonists
ES2948793T3 (en) * 2018-09-18 2023-09-19 Bristol Myers Squibb Co Cycloheptylic acids as LPA antagonists
CN113366000A (en) * 2018-09-18 2021-09-07 百时美施贵宝公司 Oxabicyclic acids as LPA antagonists
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI843503B (en) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa receptor antagonists and uses thereof
KR102913125B1 (en) 2020-06-03 2026-01-20 길리애드 사이언시즈, 인코포레이티드 LPA receptor antagonists and uses thereof
CA3218917A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022241023A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240115978A (en) 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 LPA receptor antagonists and uses thereof
AR128613A1 (en) 2022-02-25 2024-05-29 Lhotse Bio Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECEPTOR

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
PH12013501136A1 (en) * 2010-12-07 2013-07-08 Amira Pharmaceuticals Inc Lysophosphatidic acid receptor antagonists and uses thereof
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
AU2012296662A1 (en) * 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
CO7131358A2 (en) 2014-12-01
CA2869541A1 (en) 2013-12-27
PE20142448A1 (en) 2015-01-28
CL2014003243A1 (en) 2015-03-20
PH12014502789A1 (en) 2015-02-09
EA201492285A1 (en) 2015-04-30
CR20140525A (en) 2015-01-12
MX2014014710A (en) 2015-03-04
SG11201407220YA (en) 2014-12-30
UA109868C2 (en) 2015-10-12
IL236088A0 (en) 2015-02-01
KR20150021057A (en) 2015-02-27
HK1206342A1 (en) 2016-01-08
JP2015520202A (en) 2015-07-16
BR112014030685A2 (en) 2017-06-27
EP2864300A1 (en) 2015-04-29
US9321738B2 (en) 2016-04-26
CN104411692A (en) 2015-03-11
MA37764A1 (en) 2016-01-29
AU2013279512A1 (en) 2014-10-16
WO2013189864A1 (en) 2013-12-27
US20150133511A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
IN2014DN09352A (en)
IN2014DN09348A (en)
IN2014DN09347A (en)
IN2014MN02598A (en)
IN2015DN01119A (en)
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
PH12016500024A1 (en) Bromodomain inhibitor
IN2014DN09434A (en)
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
MX2016002794A (en) Antiproliferative compounds.
IN2014DN06869A (en)
MX340574B (en) Imidazo pyrazines.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2015001657A (en) Lpar - substituted cyanopyrazole compounds.
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
IN2013DN02555A (en)
MX2014001862A (en) 5-cycloalkyl- or 5-heterocyclyl-nicotinamides.
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2015002755A3 (en) Compounds for the treatment of malaria
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions